Trade

with

Tekmira Pharmaceuticals Corp
(NASDAQ: TKMR)
AdChoices
21.76
-1.05
-4.60%
Pre-Market :
22.30
+0.54
+2.48%

Open

23.15

Previous Close

22.81

Volume (Avg)

2.43M (5.16M)

Day's Range

21.46-23.27

52Wk Range

7.17-31.48

Market Cap.

481.03M

Dividend Rate ( Yield )

-

Beta

0.64

Shares Outstanding

22.11M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 15.46M

    • Net Income

    • -14.06M

    • Market Cap.

    • 481.03M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -194.67

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.64

    • Forward P/E

    • -12.76

    • Price/Sales

    • 24.15

    • Price/Book Value

    • 4.57

    • Price/Cash flow

    • 10,000.00

      • EBITDA

      • -11.54M

      • Return on Capital %

      • -36.56

      • Return on Equity %

      • -46.76

      • Return on Assets %

      • -36.56

      • Book Value/Share

      • 4.76

      • Shares Outstanding

      • 22.11M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Outperform
        • 1 Year Price Target

        • 36.88

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -36.30

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 9.91

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -79.19

            • 82.75

            • Pre-Tax Margin

            • -194.67

            • 39.38

            • Net Profit Margin

            • -194.67

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -22.60

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -13.10

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 7.20

              • 2.92

              • Quick Ratio

              • 7.16

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.26

              • 2.21

              • Book Value/Share

              • 4.76

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -13.64

                • 188.68

                • P/E Ratio 5-Year High

                • -17.96

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.74

                • 124.82

                • Price/Sales Ratio

                • 26.53

                • 8.72

                • Price/Book Value

                • 5.03

                • 7.95

                • Price/Cash Flow Ratio

                • 10,000.00

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -46.76

                    (-19.90)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -36.56

                    (-10.00)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -46.76

                    (-19.90)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.19

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -12.15M
                  Operating Margin
                  -78.59
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  10,000.00
                  Ownership

                  Institutional Ownership

                  37.58%

                  Top 10 Institutions

                  32.95%

                  Mutual Fund Ownership

                  13.77%

                  Float

                  96.36%

                  5% / Insider Ownership

                  -

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Franklin Biotechnology Discovery

                  •  

                    1,633,700

                  • 30.80

                  • 7.41

                  • Franklin Biotechnology Discovery Fund

                  •  

                    695,300

                  • -6.26

                  • 3.15

                  • BlackRock Health Sciences Opps Port

                  •  

                    337,500

                  • 0.00

                  • 1.53

                  • ZI BlackRock Global Fds Wld Health Sci

                  •  

                    113,900

                  • 0.00

                  • 0.52

                  • RBC O'Shaughnessy All Cdn Equity GIF

                  •  

                    82,282

                  • 61.90

                  • 0.37

                  • BlackRock Health Sciences

                  •  

                    25,200

                  • 0.00

                  • 0.12

                  • Pacific Select Fund Health Sciences

                  •  

                    24,000

                  • 0.00

                  • 0.11

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Franklin Advisers, Inc.

                  •  

                    2,271,700

                  • +4.61%

                  • 10.30

                  • BMO Asset Management Inc.

                  •  

                    824,596

                  • +2.71%

                  • 3.74

                  • Wells Capital Management Inc.

                  •  

                    785,138

                  • -0.43%

                  • 3.56

                  • AllianceBernstein LP

                  •  

                    707,077

                  • +57.31%

                  • 3.20

                  • Baker Bros Advisors LLC

                  •  

                    484,156

                  • 0.00%

                  • 2.19

                  • Awm Investment Company Inc

                  •  

                    470,595

                  • +11.90%

                  • 2.13

                  • BlackRock Advisors LLC

                  •  

                    416,200

                  • -0.19%

                  • 1.89

                  • Bogle Investment Management L P

                  •  

                    240,006

                  • -38.56%

                  • 1.09

                  • Renaissance Technologies Corp

                  •  

                    150,200

                  • +500.80%

                  • 0.68

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Cyclical

                  Style

                  Small Growth

                  Tekmira Pharmaceuticals Corp was incorporated on October 6, 2005. The Company develops ribonucleic acid interference therapeutic product candidates as well as provides its lipid nanoparticle delivery technology to pharmaceutical part...moreners in the Canada. The Company’s internal product development candidates include TKM-PLK1, an oncology product candidate that is in Phase I clinical trials to kill cancer cells; and TKM-Ebola, an antiviral product, which is in Phase I of clinical trials for the treatment of the Zaire species of Ebola virus infection. In addition, the Company has licenses from Alnylam targeting two validated oncology targets, WEE1 and CSN5; and to develop TKM-ALDH2, a systemically delivered RNAi therapeutic that utilizes lipid nanoparticle technology for the treatment of alcohol dependen...morece.lessless

                  Key People

                  Dr. Mark J. Murray,PhD

                  CEO/Director/President

                  Dr. Daniel Kisner, M.D.

                  Director/Chairman of the Board

                  Mr. Ian C. Mortimer

                  CFO/Executive VP, Divisional

                  Dr. Ian MacLachlan,PhD

                  Chief Scientific Officer/Executive VP

                  Dr. Peter Lutwyche,PhD

                  Vice President, Divisional

                  • Tekmira Pharmaceuticals Corp

                  • 100 - 8900 Glenlyon Parkway

                  • Burnaby, BC V5J 5J8

                  • CAN.Map

                  • Phone: +1 604 419-3200

                  • Fax: +1 604 419-3201

                  • tekmirapharm.com

                  Incorporated

                  2005

                  Employees

                  92

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: